Skip to main content

Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract Aim: 

There is currently no well-accepted therapy for central nervous system Langerhans cell histiocytosis (CNS-LCH), a neuroinflammatory disease clinically characterized by often progressive, neurological symptoms including ataxia, dysarthria, dysphagia, hypertonicity, intellectual impairment and behavioural abnormalities. We applied immunomodulative/anti-inflammatory treatment on a patient with progressive CNS-LCH disease. Method: 

Intravenous immunoglobulin (IVIG) was administered monthly for 15 years to a patient with severe, image-verified neurodegenerative CNS-LCH. Results: 

During the IVIG treatment, the neurological deterioration initially appeared to be haltered, but over time there was still some deterioration. Conclusions: 

IVIG may be beneficial in partly haltering CNS-LCH neurodegeneration, but further studies are needed.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Central nervous system; Intravenous immunoglobulin; Langerhans cell histiocytosis; Therapy

Document Type: Research Article

Publication date: 2011-07-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more